Galmed Pharmaceuticals (GLMD) Change in Account Payables (2013 - 2025)
Galmed Pharmaceuticals (GLMD) recorded quarterly Change in Account Payables of $44000.0 in Q4 2025, up 117.32% quarter-over-quarter from -$254000.0 in Q3 2025, and up 104.82% on a YoY basis from $21482.4 in Q4 2024.
Galmed Pharmaceuticals (GLMD) Change in Account Payables (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Change in Account Payables history runs 13 years deep, the most recent figure standing at $44000.0 for Q4 2025.
- In Q4 2025, Change in Account Payables rose 104.82% year-over-year to $44000.0; the TTM figure through Dec 2025 stood at -$23000.0 (up 95.97% YoY), while the FY2025 annual figure was -$23000.0, up 95.97% from the prior year.
- Change in Account Payables was $44000.0 for Q4 2025 at Galmed Pharmaceuticals, up from -$254000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.6 million in Q4 2023 to a low of -$1.2 million in Q3 2023.
- Historically, Change in Account Payables has averaged $43100.0 across 5 years, with a median of $30500.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 3206.38% in 2023, then sank 49700.0% in 2024.
- A 5-year view of Change in Account Payables shows it stood at -$111000.0 in 2021, then jumped by 142.34% to $47000.0 in 2022, then surged by 3206.38% to $1.6 million in 2023, then plunged by 158.75% to -$913000.0 in 2024, then jumped by 104.82% to $44000.0 in 2025.
- The last three Change in Account Payables figures came in at $44000.0 (Q4 2025), -$254000.0 (Q3 2025), and $553000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Jun 30, 2025 | 553,000.00 |
| Jun 30, 2025 | 553,000.00 |
| Mar 31, 2025 | -366,000.00 |
| Mar 31, 2025 | -366,000.00 |
| Dec 31, 2024 | -913,000.00 |
| Dec 31, 2024 | -913,000.00 |
| Sep 30, 2024 | 821,000.00 |
| Sep 30, 2024 | 821,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | -496,000.00 |
| Mar 31, 2024 | -496,000.00 |
| Dec 31, 2023 | 1.55 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | -1.19 Mn |
| Sep 30, 2023 | -1.19 Mn |